Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568 Aug 28, 2024 07:07AM
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area May 30, 2024 02:30AM
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568 Apr 16, 2024 02:30AM
Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease Nov 24, 2023 03:35AM
Sosei Heptares and Kallyope Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases Nov 10, 2023 01:35AM
View Older Stories

Nov 7, 2023 04:00AM Sosei Heptares’ President & CEO and Head of UK R&D to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2023
Nov 5, 2023 06:35PM Sosei Heptares’ Partner, Pfizer, Progresses Its GLP-1 Receptor Agonist PF-06954522 into a Phase 1 Trial
Oct 31, 2023 03:30AM Sosei Heptares Will Receive US$3.75 Million Payment in Multi-Target Partnership
Oct 25, 2023 04:00AM Sosei Heptares to Host R&D Day Highlighting its Innovative R&D and Late-Stage Development Progress
Oct 18, 2023 03:04AM Sosei Heptares’ President & CEO Chris Cargill Wins Executive of the Year at the Citeline Pharma Intelligence Awards Japan 2023
Oct 10, 2023 02:30AM Sosei Heptares and PharmEnable Therapeutics Expand Drug Discovery Collaboration
Oct 4, 2023 12:00PM Sosei Heptares and Verily Nominate First G-protein-coupled receptor Target for Therapeutic Development
Aug 10, 2023 02:51AM Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732
Aug 4, 2023 02:37AM Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2023
Mar 23, 2023 03:00AM Sosei Heptares Confirms Changes to its Board and Executive Management Team at Annual Shareholders’ Meeting
Mar 14, 2023 08:05PM Sosei Heptares Announces Change of Market Listing Segment to the Tokyo Stock Exchange Prime Market
Mar 8, 2023 03:00AM Sosei Heptares Receives Approval for Change of Market Listing Segment to the Tokyo Stock Exchange Prime Market
Feb 14, 2023 01:30AM Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2022
Jan 25, 2023 01:30AM Sosei Heptares Webinar Presentation for FY2022 Financial Results
Jan 5, 2023 02:37AM Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders
Dec 20, 2022 07:01PM Sosei Heptares' Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity
Dec 20, 2022 01:30AM Sosei Heptares to present at 41st Annual J.P. Morgan Healthcare Conference
Dec 15, 2022 07:01PM Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases
Dec 13, 2022 01:30AM Sosei Heptares Receives $10 Million Milestone Payment in Discovery Collaboration with AbbVie Targeting Inflammatory Diseases
Dec 8, 2022 01:30AM Sosei Heptares Enters R&D Agreements with the University of Oxford and KU Leuven to Identify and Validate Key GPCRs Driving Gastrointestinal and Immune Disorders
Nov 11, 2022 01:30AM Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2022
Nov 9, 2022 03:00AM Sosei Heptares’ President & CEO and Head of UK R&D to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2022
Nov 8, 2022 03:00AM PrecisionLife to Evaluate Precision Medicine Potential of Sosei Heptares Neuroscience GPCR Target
Oct 27, 2022 07:05PM Sosei Heptares’ Partner Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia
Sep 27, 2022 02:30AM Sosei Heptares to host R&D Day highlighting its innovative R&D and translational medicine approaches to drug discovery and strong pipeline momentum
Sep 1, 2022 07:05PM Sosei Heptares Wins Licensing Deal of the Year and Executive of the Year at the Inaugural Informa Pharma Intelligence Awards Japan
Aug 10, 2022 02:45AM Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2022
Aug 4, 2022 07:05PM Sosei Heptares’ Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development under Multi-Program Collaboration with Neurocrine Biosciences
Aug 1, 2022 07:05PM Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases
Jul 21, 2022 07:05PM Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials
May 26, 2022 02:30AM Sosei Heptares Expands UK R&D Operations to Second Site within Granta Park, Cambridge
May 17, 2022 02:30AM Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR Targets for Drug Discovery
May 13, 2022 02:30AM Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2022
Apr 26, 2022 02:30AM Sosei Heptares to Embed Agile Operating Model and Enhance its Translational Medicine Capabilities through Strategic Collaboration with Weatherden
Mar 24, 2022 03:00AM Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage of its Evolution
Feb 10, 2022 03:09AM Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2021
Feb 1, 2022 05:11AM Sosei Group Corporation Proposes Changes to its Leadership Team as Part of Succession Plan to Drive the Company Through the Next Stage of its Evolution
Jan 6, 2022 05:07AM Sosei Heptares and Verily will collaborate to generate novel drug candidates against GPCR targets for immune-mediated diseases
Dec 28, 2021 01:30AM Sosei Heptares to present at 40th Annual J.P. Morgan Healthcare Conference
Dec 23, 2021 06:05PM Sosei Heptares Announces Antitrust Clearance of License Agreement with Neurocrine Biosciences
Dec 16, 2021 07:35AM Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies against GPCR Targets
Dec 16, 2021 07:30AM Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies Against GPCR Targets
Dec 7, 2021 03:00AM Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19
Nov 22, 2021 08:00AM Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders
Nov 12, 2021 02:51AM Sosei Heptares Notes that its Partnered Adenosine A2a Antagonist Imaradenant (AZD4635) has been Removed from AstraZeneca's Clinical Pipeline
Nov 11, 2021 02:10AM Sosei Heptares Operational Highlights and Consolidated Results for Nine Months ended 30 September 2021
Aug 12, 2021 03:00AM Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half 2021
Jul 6, 2021 08:10AM Sosei Heptares and InveniAI Enter a Multi-Target AI-Powered and GPCR-Focused Drug Discovery Collaboration
Jul 6, 2021 03:00AM Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration
Jun 23, 2021 03:00AM Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven
View Older Stories